PMID- 29962407
OWN - NLM
STAT- MEDLINE
DCOM- 20181024
LR  - 20191210
IS  - 1347-5215 (Electronic)
IS  - 0918-6158 (Linking)
VI  - 41
IP  - 7
DP  - 2018
TI  - Development of a Screening System for Targeting Carriers Using Peptide-Modified 
      Liposomes and Tissue Sections.
PG  - 1107-1111
LID - 10.1248/bpb.b18-00151 [doi]
AB  - Liposomes have been used as targeting carriers for drug delivery systems (DDSs), 
      and the carriers are able to be modified with targeting ligands, such as 
      antibodies and peptides. To evaluate the targetability of DDS carriers modified 
      with a targeting ligand, culture cells expressing the targeting molecules as well 
      as small animals are used. Furthermore, in vitro and in vivo screening analyses 
      must be repeatedly performed. Therefore, it is important to establish an easy and 
      high-precision screening system for targeting carriers. With this aim, we focused 
      that whether this ex vivo system could easily support assessment of interaction 
      between targeting ligand and its receptor under physiological environment and 
      further screen the DDS carrier-modified with targeting moiety. We examined 
      targeting ability via in vitro, ex vivo, and in vivo analyses using integrin 
      alpha(v)beta(3)-targeting C16Y-L. For the in vitro analysis, the cellular uptake of 
      C16Y-L was higher than that of control liposomes in colon26 cells. For the ex 
      vivo analysis, we performed an immunohistochemical analysis using colon26 tumor 
      sections. C16Y-L was specifically attached to the tumor sections, as found in the 
      in vitro analysis. Moreover, to evaluate the ex vivo-in vivo correlation, we 
      examined the intratumoral localization of C16Y-L. This result showed that C16Y-L 
      was accumulated not only in the tumor tissue but also in the tumor vasculature 
      after the intravenous injection of C16Y-L, suggesting that the ex vivo 
      peptide-modified liposomal analysis was correlated with the in vivo analysis. 
      Thus, the ex vivo peptide-modified liposomal analysis may be an easy and rapid 
      screening system with high-precision and for consideration in in vivo conditions.
FAU - Negishi, Yoichi
AU  - Negishi Y
AD  - Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, 
      Tokyo University of Pharmacy and Life Sciences.
FAU - Hamano, Nobuhito
AU  - Hamano N
AD  - Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, 
      Tokyo University of Pharmacy and Life Sciences.
FAU - Sato, Hinako
AU  - Sato H
AD  - Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, 
      Tokyo University of Pharmacy and Life Sciences.
FAU - Katagiri, Fumihiko
AU  - Katagiri F
AD  - Department of Clinical Biochemistry, School of Pharmacy, Tokyo University of 
      Pharmacy and Life Sciences.
FAU - Takatori, Kyohei
AU  - Takatori K
AD  - Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, 
      Tokyo University of Pharmacy and Life Sciences.
FAU - Endo-Takahashi, Yoko
AU  - Endo-Takahashi Y
AD  - Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, 
      Tokyo University of Pharmacy and Life Sciences.
FAU - Kikkawa, Yamato
AU  - Kikkawa Y
AD  - Department of Clinical Biochemistry, School of Pharmacy, Tokyo University of 
      Pharmacy and Life Sciences.
FAU - Nomizu, Motoyoshi
AU  - Nomizu M
AD  - Department of Clinical Biochemistry, School of Pharmacy, Tokyo University of 
      Pharmacy and Life Sciences.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Integrin alphaVbeta3)
RN  - 0 (Ligands)
RN  - 0 (Liposomes)
RN  - 0 (Oligopeptides)
RN  - 0 
      (aspartyl-phenylalanyl-lysyl-leucyl-phenylalanyl-alanyl-valyl-tyrosyl-isoleucyl-lysyl-tyrosyl-arginine)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/administration & dosage
MH  - Cell Line, Tumor
MH  - Chemistry, Pharmaceutical/*methods
MH  - Drug Delivery Systems/*methods
MH  - High-Throughput Screening Assays/*methods
MH  - Human Umbilical Vein Endothelial Cells
MH  - Humans
MH  - Integrin alphaVbeta3/metabolism
MH  - Ligands
MH  - Liposomes
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Nanoparticles/*chemistry
MH  - Neoplasms/drug therapy
MH  - Oligopeptides/chemistry
MH  - Xenograft Model Antitumor Assays
OTO - NOTNLM
OT  - C16Y peptide
OT  - drug delivery system
OT  - nano carrier
OT  - screening array
EDAT- 2018/07/03 06:00
MHDA- 2018/10/26 06:00
CRDT- 2018/07/03 06:00
PHST- 2018/07/03 06:00 [entrez]
PHST- 2018/07/03 06:00 [pubmed]
PHST- 2018/10/26 06:00 [medline]
AID - 10.1248/bpb.b18-00151 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2018;41(7):1107-1111. doi: 10.1248/bpb.b18-00151.